Vimarsana
Biggest News Aggregation in the World

Bymarke Neumann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bymarke Neumann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bymarke Neumann Today - Breaking & Trending Today

Lifetime Achievement, Pioneer Awards presented at American Transplant Congress - Vimarsana News

Lifetime Achievement, Pioneer Awards presented at American Transplant Congress

PHILADELPHIA — Organizers of the American Transplant Congress announced award winners in transplantation research and achievements, including the Pioneer Award and the Lifetime Achievement Award.The awards were presented here on behalf of the American Society of Transplantation (AST), American Society of Transplant Surgeons (ASTS) and the American Journal of Transplantation.

Source: healio.com
Drug treatment ineffective in reducing mortality risk of patients with CKD, depression - Vimarsana News

Drug treatment ineffective in reducing mortality risk of patients with CKD, depression

Patients with chronic kidney disease who received medication to treat their depression did not see a reduction in adverse health risks for hospitalizations and mortality, a recently published study shows. “The extent to which depression affects the progression of chronic kidney disease (CKD) and leads to adverse clinical outcomes remains inadequately understood,” Rosalba Hernandez,

Source: healio.com
American Transplant Congress program addresses perfusion, equity and organ procurement - Vimarsana News

American Transplant Congress program addresses perfusion, equity and organ procurement

Editor’s note: Healio | Nephrology News & Issues interviewed John Friedewald, MD, and Roberto Hernandez-Alejandro, MD, about their roles as conference chairpersons and highlights of the agenda for the American Transplant Congress.The American Transplant Congress (ATC) will take place June 1-5 at the Pennsylvania Convention Center in Philadelphia.

Source: healio.com
Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk - Vimarsana News

Study: Semaglutide slowed progression of CKD, cut cardiovascular events, mortality risk

Use of the drug semaglutide in patients with type 2 diabetes significantly reduced the risk of major kidney disease events, cardiovascular outcomes and all-cause mortality vs. placebo, newly published data show.“These benefits signify a profound clinical impact saving kidneys, hearts and lives for patients with type 2 diabetes and chronic kidney disease,” Vlado Perkovic, MB, PS, PhD,

Source: healio.com
Study finds clinicians do not consistently use algorithms when dosing Mircera - Vimarsana News

Study finds clinicians do not consistently use algorithms when dosing Mircera

LONG BEACH, Calif. — Clinicians do not consistently use algorithms for dosing methoxy polyethylene glycol-epoetin beta when treating patients with anemia, presented research shows. “Multiple dosing algorithms exist for the use of [methoxy polyethylene glycol-epoetin beta] MPG-EPO [Mircera, Vifor Pharma],” Namrata Shrestha, MD, of the University of the Incarnate Word, San

Source: healio.com